INTRODUCTION AND OBJECTIVES:
Hemorrhagic cystitis is a highly-morbid inflammatory bladder disease associated with nitrogen mustard alkylating agents, most notably cyclophosphamide. Acrolein, a reactive oxygen species metabolite of cyclophosphamide, has been shown to silence DNA damage repair genes via global methylation pathways. 8-oxoguanine DNA glycosylase (Ogg1) is one such silenced base excision repair enzyme that can restore DNA integrity. Subsequent inflammation from the accumulation of DNA damage results in bladder smooth muscle pyroptotic cell death. We hypothesized that reversing inflammasome-induced imprinting and gene silencing in the bladder smooth muscle could prevent hemorrhagic cystitis.
METHODS: Experiments were carried out using cultured detrusor fibroblasts, B6 wild-type mice, and Ogg1 knockout mice. Hemorrhagic cystitis was induced with either cyclophosphamide or acrolein. Mesna, the current standard of care treatment to prevent hemorrhagic cystitis; Nicotinamide, a vitamin B-3 analog shown to ameliroate bladder inflammation; and suberoylanilide hydroxamic acid, a histone deacetylase (HDAC) inhibitor with anti-inflamatory properties, were added to treatment groups. Harvested tissues and cells were subjected to bisulfite sequencing and chromatin immunoprecipitation analysis to evaluate DNA methylation patterns and epigenetic imprinting.
RESULTS: There was enhanced recruitment of Dnmt1 and Dnmt3b to the Ogg1 promoter in acrolein treated bladder fibroblasts as demonstrated by the pattern of CpG-island methylation and resultant bisulfite sequencing. Accumulation of reactive oxygen species with spontaneous pyroptotic signaling was found in Ogg1 knockout detrusor cells. Suberoylanilide hydroxamic acid restored Ogg1 expression to physiologic levels moreso than either nicotinamide or Mesna in all hemorrhagic cystitis models. Additionally, suberoylanilide hydroxamic acid restored histologically-visible cyclophosphamide-induced bladder damage to that of normal untreated control mice.
CONCLUSIONS: The pattern of epigenetic imprinting induced by inflammation suggests a novel therapeutic target for the treatment of hemorrhagic cystitis. HDAC inhibitors can reactivate Ogg1 expression by altering DNA methylation through Dnmt3B regulation. More broadly, the data suggest that re-programming epigenetic imprinting could limit the inflammatory process induced by not only cyclophosphamide but by a multitude of other toxic insults as well. show the anti-inflammatory cytokine interleukin-10 (IL-10) attenuates fibrosis in a murine model. We and others have shown IL-10 regulates angiogenesis and endothelial progenitor recruitment during dermal and ischemic cardiac tissue repair. We hypothesize that IL-10 can promote angiogenesis and prevent microvascular rarefaction in a murine UUO model.
METHODS: 8 week-old C57BL/6J (WT) mice and IL-10 null male mice were injected with lenti-IL-10/lenti-GFP (1x10 10 IU) under the renal capsule. Three days after injection, UUO was performed. 14 days after UUO, UUO/sham kidneys and serum were collected for RNA, ELISA and immunohistochemical analysis of VEGF and TGFb isoforms. Primary fibroblasts were isolated from 8-10 week-old male WT mice. IL-10 (50 ng/ml or 200 ng/ml) was added to cultures. VEGF and TGFb-1 gene expressions were assessed by qPCR at 1, 2, 3 and 6h. Levels of TGFb-1 and TGFb-3 were determined at 48h by ELISA. Data presented as meanAESD, n¼3/treatment group. P value by ANOVA.
RESULTS: IL-10 treatment, in vitro, increased VEGF expression (related to physiologic angiogenesis) and altered the expression of TGFb isoforms (related to pathologic fibrosis). Lenti-Il10 treatment in mice with UUO reduced fibrotic changes between tubules (45AE7%, p<0.05) and attenuated tubular dilatation (p<0.05, n¼30/group). CD31, an endothelium marker essential to preserving tubular integrity, was normally expressed in healthy kidney parenchyma and decreased after UUO. IL-10 null mice showed a lower basal level of CD31 than WT mice. In both WT and IL-10 null mice, IL-10 treatment preserved CD31, suggesting a role in rescuing integral peritubular capillaries.
CONCLUSIONS: Ureteral obstruction can cause remodeled renal architecture and decrease in renal function. Our results in a murine UUO model show that IL-10 can effectively promote angiogenesis in vitro and prevent microvascular rarefaction in vivo. Mice treated with IL-10 show decreased fibrotic change and increased markers for tubular integrity. These results from the in vivo studies of UUO, and the in vitro studies of IL-10 0 s influence in angiogenesis and fibrosis of the kidney, may lead to novel treatments for the sequelae of urinary tract obstruction. treatment to halt renal fibrosis progression to CKD is largely lacking. Connective tissue growth factor (CTGF) renal upregulation is evident in various nephropathies including obstructive uropathy and is linked to fibrosis progression. Precise mechanisms of CTGF contribution to the maladaptive phenotype (e.g., epithelial dedifferentiation, growth arrest, fibrotic factor induction) however, are largely unknown.
METHODS: Human kidney tubular epithelial cells (HK-2) were stably transduced with either control or CTGF expression via lentiviral transduction to mimic CTGF induction in kidney injury. Western analysis was used to confirm CTGF overexpression and to investigate the effects of CTGF overexpression on various fibrotic markers. Epithelial cell-cell communication studies involved transfer of conditioned media from control or CTGF stably expressing epithelial cells to similarly seeded normal HK-2 cultures. Microscopy was used to evaluate cell morphologic changes. Cell death is confirmed by Annexin staining.
RESULTS: Prolonged epithelial CTGF overexpression resulted in upregulation of pro-fibrotic factors including fibronectin and plasminogen activator inhibitor 1 (PAI-1), induction of plasticity maker, vimentin, and downregulation of expression of epithelial cell adhesion molecule (E-cadherin), compared to vector transduced HK-2 controls. Epithelial cells with CTGF overexpression assume a mesenchymal morphology and undergo growth inhibition. Cell-cell communication experiments reveal that paracrine factors secreted by CTGF expressing HK-2 cells trigger growth inhibition and a fibrotic response in normal HK-2 cells. CTGF expression in older epithelial cultures also induces markers of DNA damage and cell death compared to similarly aged control vector transduced cultures.
CONCLUSIONS: Epithelial CTGF induction promotes upregulation of fibrotic factors, induction of epithelial dedifferentiation, suppression of cell growth and orchestrates (via paracrine mechanisms) dysfunction in normal renal epithelia. CTGF, therefore, could be an attractive drug target against renal fibrosis and CKD progression.
Source of Funding: NIH RO1 GM 057242; Department of Veterans Affairs

PD12-10 KIDNEY INJURY MOLECULE-1 AS A POTENTIAL URINARY BIOMARKER OF HYDRONEPROSIS MAY NOT BE AFFECTED BY INFLAMMATORY CAUSES IN THE URINARY TRACT
Daniel Olvera-Posada*, Monterrey, Mexico; Stephen Pautler, Alp Sener, John Denstedt, Hassan Razvi, London, Canada INTRODUCTION AND OBJECTIVES: Newly discovered biomarkers have been used to assess renal function in several clinical situations, and diverse studies have suggested a relationship between urinary tract obstruction and increased levels of these biomarkers. It has been postulated that some inflammatory conditions may affect the expression of these markers precluding its use in our population. We planned to evaluate the urinary levels of Kidney Injury Molecule-1 in a set of urological patients to determine which factors may be associated with its expression.
METHODS: From a prospective observational cohort study, we included patients with hydronephrosis caused by renal stone disease or ureteric stricture, and patients with non-obstructive nephrolithiasis. Demographical, clinical and radiological characteristics were evaluated before and after surgical treatment. Urinary normalized KIM-1 concentration was measured using ELISA analyses in three different occasions, one preoperative and in two postoperative assessments. Nonparametric tests were used to compare KIM-1 levels during follow-up. The presence of stone disease, double J stent and hydronephrosis were noted and dichotomized. Correlations between biomarkers' levels and clinical or radiological characteristics were assessed using Spearman's correlation coefficient.
RESULTS: Forty-eight patients and eleven controls were included in the final analysis. First and second postoperative assessment were performed with a median of 17 days (IQR 9.5) and 59 days (IQR 34) after the surgical procedure. Patients with hydronephrosis showed a higher KIM-1 concentration than no-hydro patients and controls (1.19 vs 0.60 ng/mg creatinine, p¼0.002). After analyzing KIM-1 expression in hydronephrosis patients exclusively, we found significantly higher levels at baseline, compared to both postoperative evaluations (p<0.001). KIM-1 showed a weak correlation with age, female gender, BMI, Charlson Comorbidity Index and presence of hydronephrosis (p<0.0001). Although, its expression was not correlated with the estimated glomerular filtration rate, leukocyturia, or presence of stone disease. The distribution of KIM-1 levels amongst patients with non-obstructive stone disease did not significantly change despite the surgical management.
CONCLUSIONS: This exploratory study found that urinary KIM-1 expression could potentially be affected by some patients' baseline characteristics. However, our results corroborate that urinary KIM-1 may be a reliable marker of hydronephrosis. 
PD12-11 DECREASED VASCULAR ENDOTHELIAL GROWTH FACTOR IN RADIATION CYSTITIS
Bernadette Zwaans*, Sarah Bartolone, Royal Oak, MI; Heinz Nicholai, Santiago de Chile, Chile; Michael Chancellor, Laura Lamb, Royal Oak, MI INTRODUCTION AND OBJECTIVES: Radiation cystitis (RC) is a severely debilitating and inflammatory condition of the bladder resulting from radiation therapy to the pelvic area for which there is no curative therapy. 5-10% of cancer patients who have received pelvic radiation will develop RC, though little is known about the histological and molecular changes that drive the disease progression. A major histological hallmark of RC is vascular damage and hemorrhaging. Therefore, our study focuses on identifying early molecular changes that drive the vascular defect observed in RC using a mouse model of RC. In addition, we aim to identify potential urine biomarkers that could identify RC development prior to the appearance of symptoms.
METHODS: Female C57BL/6 mice received a single dose of 40 Gy radiation delivered specifically to the bladder using a Small Animal Radiation Research Platform, a technique that simulates radiation treatment in human patients. Bladder tissues were harvested at 2 and 12 weeks post irradiation and processed for histology or molecular analysis. In addition, changes in vascular endothelial growth factor (VEGF) and cytokine/chemokine expression were analyzed in human urine samples from cancer survivors that received pelvic radiation.
RESULTS: Bladder irradiation was well tolerated by mice. By 12 weeks, decreased bladder vascularization was detected in irradiated animals as was an increase in inflammatory cells clustered around blood vessels. This vascularization defect coincided with a loss of VEGF levels. Decreased VEGF expression was also identified in urine from symptomatic RC patients, in comparison to age-matched controls.
CONCLUSIONS: Radiation therapy for the treatment of pelvic tumors can cause severe damage to the bladder that can develop into radiation (hemorrhagic) cystitis. Blood loss through the urine is a major hallmark of RC and is caused by vascular defects that are currently not well understood. In this study irradiated mouse bladders developed reduced vascularization which coincided with a loss of VEGF expression. In addition, low levels of VEGF were also identified in the urine of symptomatic RC patients. Our findings suggest VEGF as a potential therapeutic target to treat the vascular defect in RC.
